Your session is about to expire
← Back to Search
Abemaciclib Combination Therapy for Advanced Breast Cancer
Study Summary
This trial looks at the safety of using abemaciclib in different combinations of drugs to treat breast cancer that has spread.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 2 trial • 105 Patients • NCT03321981Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been treated with a nonsteroidal aromatase inhibitor for my metastatic disease and may currently be on exemestane.My cancer progressed despite treatment with CDK4/6 inhibitors and hormone therapy.I have brain metastases treated with radiotherapy or had neurological changes within the last 14 days.Your recent heart test showed certain abnormal results like irregular heartbeats, signs of heart problems, or a prolonged QT interval.I have cancer that has spread to my brain and haven't had brain radiation.I have not had a heart attack or severe heart issues in the last 6 months.I have type 1 diabetes, had gestational diabetes, or my type 2 diabetes is well-controlled with pills.My breast cancer is HER2 positive and has spread to other parts.I have not had hormone therapy for my cancer, except for letrozole.I have not had hormone therapy for my metastatic disease, except for anastrozole.I have been treated with a nonsteroidal aromatase inhibitor for my metastatic disease.I am fully active and can carry on all pre-disease activities without restriction.I am willing to have tumor biopsies before and after the study treatment.I stopped all breast cancer treatments 21 days ago, except for hair loss or nerve issues.I have been treated with a nonsteroidal aromatase inhibitor for my cancer and may currently be on exemestane or exemestane + everolimus.For parts G, H, and I, you have a disease that can be measured using a specific set of guidelines.I've had chemotherapy for metastatic disease and my heart function is normal.I've had chemotherapy for my metastatic disease and my heart function is normal.My cancer can be measured or evaluated, especially in the bones.My blood, liver, and kidney functions are all within normal ranges.My breast cancer has spread, is worsening quickly, and is affecting my organs.You have received certain types of medication before, depending on the part of the study.I am post-menopausal or pre-menopausal using ovarian suppression treatment.I may have had hormone therapy for my cancer and could be on tamoxifen now.My breast cancer is HR+ and HER2-.I have had chemotherapy for cancer that has spread, but may also have had it as part of initial treatment.
- Group 1: LY2835219 + Exemestane + Everolimus Dose Expansion
- Group 2: LY2835219 + Anastrozole
- Group 3: LY2835219 + Exemestane
- Group 4: LY3023414 + LY2835219 + Fulvestrant Dose Expansion
- Group 5: LY2835219+ Trastuzumab Dose Escalation
- Group 6: LY2835219 + Exemestane + Everolimus Dose Escalation
- Group 7: LY2835219 + Letrozole
- Group 8: LY3023414 + LY2835219 + Fulvestrant Dose Escalation
- Group 9: LY2835219 +Trastuzumab + Pertuzumab +Loperamide Dose Expansion
- Group 10: LY2835219 + Tamoxifen
- Group 11: LY2835219 +Trastuzumab +Pertuzumab +Loperamide Dose Escalation
- Group 12: LY2835219+ Trastuzumab Dose Expansion
- Group 13: LY2835219 + Endocrine Therapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What medical conditions are Endocrine therapies most often prescribed for?
"Endocrine therapy, which is used to target estrogen receptors, has the potential to combat a range of illnesses such as disease progression, diarrhea, and pulmonary issues."
Are there vacancies currently available for participants of this research?
"At present, this trial is not open for enrollment. The study was first made available on March 10th 2014 and last updated August 8th 2022; however, if you are looking for other clinical trials there are 2287 studies focusing on breast cancer that are still accepting patients and 613 endocrine therapy related experiments."
Have any prior experiments been conducted related to Endocrine treatment?
"Endocrine therapy was initially examined in 1994 at Queen Mary University of London. Since then, a total of 1272 trials have been finished, and 613 are presently active - notably there is a high concentration of research conducted out of Nashville, Tennessee."
At which locations is this research experiment being conducted?
"Patients in need of this medical intervention can be enrolled at Tennessee Oncology PLLC, Providence Cancer Center Oncology Hematology Care and University of North carolina at Chapel Hill. Additionally, there are 16 other enrolment sites across the United States."
Has Endocrine therapy received authorization from the FDA yet?
"We gave endocrine therapy a score of 1 on our scale, indicating that while it has been trialled before, there is limited evidence to support its efficacy and safety."
To what extent is this experiment being conducted with participants?
"At this time, no patients are being enrolled in the trial. The study was initially released on March 10th 2014 and has since been updated as recently as August 8th 2022. However, if you wish to explore alternative options for participation there are currently 2287 studies actively seeking out individuals with breast cancer and 613 endocrine therapy trials looking for participants."
Share this study with friends
Copy Link
Messenger